Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Feb;35(2):587-601.
doi: 10.1007/s11695-025-07669-z. Epub 2025 Jan 8.

Comparative Analysis of Renal Function Outcomes Following Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Systematic Review and Meta-analysis

Affiliations
Meta-Analysis

Comparative Analysis of Renal Function Outcomes Following Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Systematic Review and Meta-analysis

Rafaela Hamada Juca et al. Obes Surg. 2025 Feb.

Abstract

Background: Obesity is a significant risk factor for chronic kidney disease (CKD), with metabolic bariatric surgery offering potential renal benefits. However, there is limited comparative data on the impact of Roux-en-Y gastric bypass (RYGB) versus laparoscopic sleeve gastrectomy (LSG) on renal function in individuals with obesity without end-stage renal disease (ESRD). The objective of this study was to compare renal function outcomes following RYGB and LSG in patients with obesity, focusing on estimated glomerular filtration rate (eGFR), serum creatinine, albumin-creatinine ratio (ACR), and serum cystatin C.

Methods: A systematic review and meta-analysis were conducted following Cochrane and PRISMA guidelines. Data from 17 observational studies (n = 3339) were analyzed. Primary outcomes included changes in eGFR, ACR, serum creatinine, and cystatin C. Secondary outcomes included excess weight loss (%EWL) and total weight loss (%TWL). Statistical analysis involved fixed and random-effects models based on heterogeneity levels.

Results: RYGB demonstrated significant improvements in eGFR (SMD = - 0.71; 95% CI - 0.89 to - 0.52, p < 0.00001) and serum cystatin C (MD = - 0.10; 95% CI - 0.17 to - 0.03, p = 0.004) compared to LSG. No significant differences were found for serum creatinine (MD = - 1.06; 95% CI - 4.42 to 2.30, p = 0.54) or ACR (MD = 1.95; 95% CI - 0.39 to 4.29, p = 0.10). RYGB also showed greater long-term weight loss, particularly at 5 years (%EWL: MD = 22.00; 95% CI 6.56 to 37.44, p = 0.005).

Conclusions: RYGB offers similar renal improvements with superior weight loss compared to LSG in individuals with obesity without ESRD. These findings emphasize the need for personalized treatment approaches and further research to validate these outcomes.

Keywords: Bariatric surgery; Gastrectomy; Gastric bypass; Obesity; Renal function.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interest: The authors declare no competing interests.

Similar articles

Cited by

References

    1. Schwartz P, Capotondo MM, Quaintenne M, et al. Obesity and glomerular filtration rate. Int Urol Nephrol. 2024;56:1663–8. - PubMed
    1. D’Agati VD, Chagnac A, De Vries APJ, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12:453–71. - PubMed
    1. Seng NSHL, Lohana P, Chandra S, et al. The fatty kidney and beyond: a silent epidemic. Am J Med. 2023;136:965–74.
    1. Sandino J, Luzardo L, Morales E, et al. Which patients with obesity are at risk for renal disease? Nephron. 2021;145(6):595–603. - PubMed
    1. Zhao L, Zou Y, Wu Y, et al. Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2023;14:1103251. - PubMed

LinkOut - more resources